MADISON, Wis., Oct. 18, 2017 /PRNewswire/ -- Exact Sciences, the manufacturer of Cologuard, announced today the four Grand Prize winners of the Green Bay Packers-Cologuard Colon Cancer Awareness Campaign. Each receives two bowl tickets to the Packers game at Lambeau Field on Sunday, October 22. Winning names were drawn from more than 1,300 entries.
The ticket winners are: Nicholas Pierson (Oshkosh, Wis.); Nathan Plitzuweit (Green Bay, Wis.); Stephanie Ronzio (Carlisle, Pa.); and Holly Setson (Smyrna, Ga.).
The Green Bay Packers and Cologuard are working to promote colorectal cancer awareness throughout the 2017 football season. Through an online pledge, ticket giveaway contest and digital campaign, the Packers-Cologuard Colon Cancer Awareness Campaign encourages screening-eligible fans age 50-plus to get checked for colon cancer and asks all Packers fans to help spread the word about the importance of screening.
"Colon cancer is the number two cancer killer in America – killing more each year than either breast or prostate cancer," said Kevin Conroy, chairman and CEO of Exact Sciences. "We thank all those pledging to help raise awareness and are proud to recognize these four Grand Prize winners with tickets to Lambeau Field on October 22."
Pledging and Prizes Continue
Fans can continue taking the Packers-Cologuard colon cancer awareness pledge by visiting the Promotions tab on Packers.com. Qualified individuals who did not win game tickets and those who take the pledge by the end of the 2017 regular season will be eligible to win runner-up prizes of Packers Pro Shop gift cards, autographed memorabilia and Cologuard t-shirts. Complete rules and details can be found on the pledge page online.
Colon cancer took the life of legendary Packers coach Vince Lombardi at age 57 and almost 50 years later remains the number two cancer killer in the United States, according to the U.S. Centers for Disease Control and Prevention.
Despite being considered one of the most preventable yet least prevented forms of cancer and having a high survival rate when treated early, millions of Americans are still reluctant to get screened for colon cancer or are not getting screened at recommended intervals. The American Cancer Society recommends most individuals at average risk should begin colorectal cancer screening at age 50.
Wisconsin-headquartered Exact Sciences is the maker of Cologuard, the only noninvasive screening option that uses the DNA found in a person's stool sample to detect colon cancer and precancerous growths. Cologuard is fully covered by Medicare and incorporated into the medical policies of the leading national health insurers, as well as a broad cross-section of local and regional health plans. To learn more, visit www.cologuardtest.com.
Scott Larrivee, Exact Sciences, 608-535-8673, email@example.com
Cologuard was approved by the FDA in August 2014 and results from Exact Sciences' prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the New England Journal of Medicine in March 2014. Cologuard is included in the American Cancer Society's (2014) colorectal cancer screening guidelines and the recommendations of the U.S. Preventive Services Task Force (2016) and National Comprehensive Cancer Network (2016). Cologuard is indicated to screen adults of either sex, 50 years or older, who are at average risk for colorectal cancer. Cologuard is not for everyone and is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. False positives and false negatives do occur. Any positive test result should be followed by a diagnostic colonoscopy. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Cologuard performance when used for repeat testing has not been evaluated or established. For more information about Cologuard, visit www.cologuardtest.com. Rx Only.
About Exact Sciences Corp.
Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. For more information, please visit the company's website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences or find Exact Sciences on Facebook.